Xa factor
Showing 1 - 25 of >10,000
Health Care Interventions and Outcomes of Major Bleedings in
Not yet recruiting
- Major Bleeding
- None (Observational study)
- (no location specified)
Nov 17, 2023
Atrial Fibrillation, Anticoagulant-induced Bleeding Trial in Seoul (Factor Xa Inhibitor)
Recruiting
- Atrial Fibrillation
- Anticoagulant-induced Bleeding
- Factor Xa Inhibitor
-
Seoul, Jongno-gu, Korea, Republic ofSeoul National university Hostpital
Apr 5, 2023
Coagulation Disorder Trial (PROTHROMPLEX TOTAL, 4F-PCC)
Not yet recruiting
- Coagulation Disorder
- PROTHROMPLEX TOTAL
- 4F-PCC
- (no location specified)
Jul 14, 2022
AORTIC VALVE DISEASES, Thromboembolism Trial in Korea, Republic of (Rivaroxaban Oral Tablet, Vitamin K antagonist(warfarin))
Recruiting
- AORTIC VALVE DISEASES
- Thromboembolism
- Rivaroxaban Oral Tablet
- Vitamin K antagonist(warfarin)
-
Bucheon, Korea, Republic of
- +8 more
Oct 11, 2022
Dose Adjustment of Enoxaparin in ICU Patients Trial in Kfar Saba (Dose adjustment of Enoxaparin in patients with sub-therapuetic
Completed
- Dose Adjustment of Enoxaparin in ICU Patients
- Dose adjustment of Enoxaparin in patients with sub-therapuetic (prophylactic) levels of factor 10a
-
Kfar Saba, IsraelMeir Medical Center
Jan 23, 2022
Urgent Surgery Trial (Andexanet alfa, Usual Care)
Not yet recruiting
- Urgent Surgery
- Andexanet alfa
- Usual Care
- (no location specified)
Jun 21, 2023
Is Anti-Factor Xa Associated With Outcome in Critical COVID-19
Completed
- Covid19
- +2 more
- The effect of LMWH
- Monitoring frequency of aFXa-levels
-
Stockholm, SwedenSödersjukhuset
Feb 24, 2022
Outcomes in Hospitalised Patients Treated With Ondexxya
Not yet recruiting
- Hemorrhage
- Andexanet alfa
- (no location specified)
Jun 12, 2023
Ondexxya for Intravenous Injection 200mg Drug Use Result
Recruiting
- Life Threatening Bleeding
- Factor Xa Inhibitor
-
Tokyo, JapanResearch Site
Jul 7, 2022
Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving
Not yet recruiting
- Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis
- Assessment the activity of anti-Xa factor.
-
Gdańsk, Pomorskie, PolandMedical University of Gdansk - Departament of Anesthesiology and
Dec 15, 2020
Contrast Agents and Oral Factor Xa Inhibitor Trial in Bursa (computerized tomography)
Completed
- Contrast Agents and Oral Factor Xa Inhibitor
- computerized tomography
-
Bursa, TurkeyBursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Oct 27, 2020
Heparin Requirements in Patients Undergoing Atrial Fibrillation
Completed
- Atrial Fibrillation
- Monitoring Anti Factor Xa level
-
Brighton, MassachusettsSt Elizabeth Medical Center
Jul 15, 2021
Dextran Sulphate on Anti-Xa Activities Measured
Completed
- Unfractionated Heparin Treatment
- measurement of anti-Xa activities
-
Bordeaux, France
- +7 more
Feb 8, 2021
Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral
Completed
- Atrial Fibrillation
- Phenprocoumon
- +3 more
-
Multiple Locations, GermanyMany Locations
Nov 24, 2020
Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and
Unknown status
- Anticoagulation
- +2 more
- Estimated anticoagulant level (conversion factor x anti-Xa activity)
- (no location specified)
Nov 30, 2020
Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy Trial in Saint Louis (aPTT guided heparin
Completed
- Left Sided Heart Failure
- +7 more
- aPTT guided heparin management
- Anti-factor Xa guided heparin management
-
Saint Louis, MissouriWashington University in St Louis School of Medicine
Feb 17, 2020
Symptomatic Aortic Stenosis, Eligible for Transcatheter Aortic Valve Replacement Trial in Worldwide (Apixaban, Standard of care)
Completed
- Symptomatic Aortic Stenosis
- Eligible for Transcatheter Aortic Valve Replacement
- Apixaban
- Standard of care
-
Paris, France
- +3 more
Feb 24, 2021
Rivaroxaban - Percutaneous Coronary Intervention
Completed
- Coronary Artery Disease
- Atrial Fibrillation
- In vitro heparin
-
Bursa, TurkeyBursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi
Sep 13, 2022
Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity Trial in Winston-Salem (Enoxaparin)
Terminated
- Anticoagulants and Bleeding Disorders
- +2 more
-
Winston-Salem, North CarolinaWake Forest University Baptist Medical Center
Dec 4, 2022
Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia Trial in Chapel Hill (rivaroxaban, )
Completed
- Sickle Cell Anemia
- Sickle Cell-Beta0-Thalassemia
- rivaroxaban
- placebo
-
Chapel Hill, North CarolinaUniversity of North Carolina - Chapel Hill
Apr 9, 2020
Venous Thromboembolism Trial in Russian Federation (Dimolegin 40 mg, Dimolegin 60 mg, Fragmin)
Active, not recruiting
- Venous Thromboembolism
- Dimolegin 40 mg
- +2 more
-
Bryansk, Russian Federation
- +14 more
Apr 25, 2022
Dose Regimen of Intravenous Unfractionated Heparin and Low
Active, not recruiting
- COVID-19
- +3 more
-
Gent, BelgiumGhent University Hospital
Oct 24, 2022
